News from bioarctic A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

01 Jul, 2020, 07:45 BST Invitation to Presentation of BioArctic's Interim Report for the Period January - June 2020 on July 10 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - June 2020 on Friday, July 1, 2020, at ...


29 Jun, 2020, 07:49 BST BioArctic and University of Oslo Sign Research Agreement to Investigate Apolipoprotein E as a Drug Target for Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) and University of Oslo, Institute of Clinical Medicine (IKM), announced today that they have signed a...


26 May, 2020, 14:51 BST Members of BioArctic's Board of Directors and Management Increase Their Shareholdings

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that seven members of the company's Board and management today have exercised options to...


07 May, 2020, 17:55 BST Report from Annual General Meeting in BioArctic (publ)

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income...


22 Apr, 2020, 07:53 BST Interim Report for the period January - March 2020

Operations performing according to plan Key events during the first quarter 2020 As of today, BioArctic has not experienced any noteworthy...


15 Apr, 2020, 07:44 BST Invitation to Presentation of BioArctic's Interim Report for the First Quarter 2020 on April 22 at 9.30 a.m. CET

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) to publish the company's Interim Report for the period January - March 2020 on Wednesday, April 22,...


03 Mar, 2020, 07:14 GMT Alzheimer Patients at Swedish Clinics to be Included in Phase 3 Study of Drug Candidate BAN2401

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company's partner Eisai will include Swedish clinics in the confirmatory...


17 Dec, 2019, 15:24 GMT BioArctic Announces Research Collaboration with Eisai Regarding BAN2401

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the initiation of a research collaboration with Eisai aimed at further studying the...


10 Dec, 2019, 09:27 GMT BioArctic Strengthens its Management Team With Two Strategic Recruitments

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) will be strengthening its management team in 2020 through two strategic recruitments. As of January 1, ...


05 Dec, 2019, 19:37 GMT BioArctic's Partner Eisai Presents Data from the Ongoing BAN2401 Phase 2b Extension Study in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that data from the ongoing BAN2401 Phase 2b open-label extension study in early...


02 Dec, 2019, 07:24 GMT BioArctic and Eisai to Present Data on BAN2401 at the Clinical Trials on Alzheimer's Disease Conference

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the 12th Clinical Trials on...


18 Nov, 2019, 23:19 GMT BioArctic Announces Results From Interim Analysis of the Phase 1/2 Study of SC0806 in Patients With Complete Spinal Cord Injury

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today the results of an interim analysis of a Phase 1/2 study of SC0806 in patients with...


18 Jul, 2019, 06:15 BST BioArctic and Eisai Present New Data Regarding BAN2401 at the Alzheimer's Association International Conference 2019

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announces that new data related to BAN2401 were presented on July 17. The presentations were held by...


15 Jul, 2019, 16:17 BST BioArctic's Co-Founder Received AAIC Lifetime Achievement Award

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced that on Sunday, its co-founder, Lars Lannfelt, professor in geriatrics at Uppsala University ...


11 Jul, 2019, 06:40 BST BioArctic and Eisai to Present BAN2401 at the Alzheimer's Association International Conference 2019

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that presentations related to BAN2401 will be given at the Alzheimer's Association...


23 May, 2019, 07:14 BST BioArctic Strengthens its Blood-brain Barrier Technology Platform With World Leading Scientist Recruitment

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has recruited the internationally renowned scientist Dr. Per-Ola...


20 May, 2019, 17:01 BST BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai...


10 May, 2019, 08:54 BST BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informed today that the Alzheimer's Clinical Trials Consortium (ACTC) and BioArctic's partner Eisai...


03 Apr, 2019, 14:57 BST BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received a non-diluting grant of MSEK 5 from Sweden's Innovation...


22 Mar, 2019, 00:01 GMT BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401...


13 Mar, 2019, 23:28 GMT BioArctic Announces Start of Phase 1 Study of ABBV-0805 for Parkinson's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is...


07 Mar, 2019, 08:35 GMT BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with...


14 Feb, 2019, 07:23 GMT BioArctic - Full Year Report January - December 2018

BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson portfolio...


13 Feb, 2019, 07:58 GMT BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the first patient in the second panel of the Phase 1/2 study now has been treated ...


11 Feb, 2019, 16:16 GMT BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805

BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of...